Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 INTrEPID Enrollment Criteria
Enrollment strategy for the INTrEPID trial. Eligible patients had severe left ventricular dysfunction for  6 months, New York Heart Association (NYHA) functional class IV symptoms for 3 months, and were required to fail 2 attempts at weaning from inotropic support separated by at least 7 days. EF = ejection fraction; LVAD = left ventricular assist device.
|
